Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dna X (SONM) Gains from Sales and Divestitures (2023 - 2025)

Historic Gains from Sales and Divestitures for Dna X (SONM) over the last 3 years, with Q3 2025 value amounting to $42956.0.

  • Dna X's Gains from Sales and Divestitures fell 1037.58% to $42956.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $42956.0, marking a year-over-year decrease of 1037.58%. This contributed to the annual value of $57621.0 for FY2024, which is 9069.19% down from last year.
  • As of Q3 2025, Dna X's Gains from Sales and Divestitures stood at $42956.0, which was down 1037.58% from $773960.0 recorded in Q2 2025.
  • Dna X's 5-year Gains from Sales and Divestitures high stood at $773960.0 for Q2 2025, and its period low was $2149.0 during Q1 2025.
  • Its 3-year average for Gains from Sales and Divestitures is $245271.4, with a median of $47929.0 in 2024.
  • Its Gains from Sales and Divestitures has fluctuated over the past 5 years, first plummeted by 9208.3% in 2024, then surged by 190793.88% in 2025.
  • Quarter analysis of 3 years shows Dna X's Gains from Sales and Divestitures stood at $619042.0 in 2023, then crashed by 90.69% to $57621.0 in 2024, then decreased by 25.45% to $42956.0 in 2025.
  • Its Gains from Sales and Divestitures was $42956.0 in Q3 2025, compared to $773960.0 in Q2 2025 and $2149.0 in Q1 2025.